Eupraxia Financial Statements From 2010 to 2024
| EPRXFDelisted Stock | USD 2.79 0.04 1.45% |
Check Eupraxia Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eupraxia Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Eupraxia financial statements analysis is a perfect complement when working with Eupraxia Pharmaceuticals Valuation or Volatility modules.
Eupraxia |
Eupraxia Pharmaceuticals Company Shares Outstanding Analysis
Eupraxia Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Eupraxia Pharmaceuticals Shares Outstanding | 21.39 M |
Most of Eupraxia Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eupraxia Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Eupraxia Pharmaceuticals has 21.39 M of shares currently outstending. This is 88.15% lower than that of the Healthcare sector and 79.98% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 96.26% higher than that of the company.
Eupraxia Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eupraxia Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Eupraxia Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eupraxia Pharmaceuticals competition to find correlations between indicators driving Eupraxia Pharmaceuticals's intrinsic value. More Info.Eupraxia Pharmaceuticals is rated # 2 in return on equity category among its peers. It is rated # 3 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eupraxia Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Eupraxia Pharmaceuticals Financial Statements
Eupraxia Pharmaceuticals stakeholders use historical fundamental indicators, such as Eupraxia Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Eupraxia Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Eupraxia Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Eupraxia Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Eupraxia Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. Eupraxia Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Eupraxia Pink Sheet
If you are still planning to invest in Eupraxia Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eupraxia Pharmaceuticals' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |